A practical reference on Intranasal delivery: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-04 and is reviewed periodically as new material appears.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
| Property | Value | Notes |
|---|---|---|
| Primary route studied | Intranasal | Also examined parenterally in animal work |
| Reported plasma half-life | Minutes to tens of minutes | Values vary widely between reports |
| Main model systems | Rodent behavioural and cell assays | Human trials are few and small |
| Principal proposed targets | GABA-A receptor, GABA transaminase | Monoamine and neurotrophic pathways also reported |
| Evidence grade | Preliminary | Limited independent replication |
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.
Quantification in biological matrices relies on liquid chromatography coupled to tandem mass spectrometry with stable-isotope internal standards. Low plasma concentrations and adsorption to container surfaces both complicate measurement. Solid-phase extraction is often needed to reduce matrix interference before injection. Reported limits of quantification differ widely between laboratories, which makes direct comparison of pharmacokinetic results difficult and limits meta-analysis.
==== Impact on the environment ==== Post incineration process, toxic ash residue is produced and is often disposed at landfills. These landfills are not protected by any barrier and the residue has the potential of reaching underground water that is often exposed to human use. The combustion of plastic material releases toxic gases that escapes and joins breathable air. Human and animal exposure to such gases can cause long term breathing and health issues. The rotation of toxic air does not only impact human well-being, but also of animals and plants. Air pollution caused by the incinerators depletes the ozone layer, causes crop and forest damage, and increases the effects of climate change. Constant exposure to such toxins and chemicals in the air could be deemed detrimental to trees and plants and could eventually lead to extinction of certain plants in specific areas. Pollution and chemical leaks also affect the fruits of trees and would cause them to be poisonous and therefore inedible.
=== Pharmacodynamics === MCCAM acts as a selective pseudo-irreversible partial agonist of the μ-opioid receptor (MOR). It shows both opioid agonist- and antagonist-like effects in animals. More specifically, it has analgesic effects, mixed reinforcing effects, appears to lack significant respiratory depression, alleviates opioid withdrawal symptoms, and provides long-lasting blockade and protection against the effects of MOR full agonists (including their reinforcing effects as well as their toxic and lethal effects, for instance in overdose). Due to its pseudo-irreversible nature, MCCAM is insurmountable by conventional reversible MOR ligands, for instance morphine, alfentanil, and naltrexone. MCCAM is buprenorphine-like in many regards, but differs from buprenorphine in its pseudo-irreversibility.
=== Film and television === Six months prior to his graduation from Guildhall, McGregor began a leading role in Dennis Potter's six-part Channel 4 series Lipstick on Your Collar (1993). He then starred in the BBC adaptation of Scarlet and Black (also 1993) with Rachel Weisz and made his film debut in Bill Forsyth's Being Human (1994). For his role in the thriller Shallow Grave (also 1994), he won an Empire Award. The film was his first collaboration with director Danny Boyle. He had a major role in the 1996 Channel 4 comedy-drama film Brassed Off, written and directed by Mark Herman. His international breakthrough followed with the role of heroin addict Mark Renton in Boyle's Trainspotting (1996), an adaptation of Irvine Welsh's novel of the same name. In 1998, McGregor played the male romantic lead role in the British film Little Voice, and rockstar Curt Wild in the film Velvet Goldmine directed by Todd Haynes. He was cast as the young Obi-Wan Kenobi in the Star Wars prequel trilogy, released between 1999 and 2005. Kenobi was originally played by Alec Guinness in the first Star Wars trilogy. McGregor's uncle, Denis Lawson, had played Wedge Antilles in the original trilogy. While the prequels received mixed reviews, McGregor's performance was well received. McGregor said making the prequels was difficult, as he had to act mostly against green screens and the dialogue was "not exactly Shakespeare". He also stated that the negative reaction to the films had been difficult.
=== Confirmation bias === Confirmation bias is the tendency for people to be more likely to engage with and believe ideas that confirm their preconceived notions. Mass media is not necessarily the root cause of the public's general misconception or judgment of people experiencing mental illness. It is, however, a way for people to confirm their existing beliefs and biases about mental illnesses.
== Biography == Born in 1937 in Rome, Mendes Nassi is descended from a line of physicians. His grandfather, Guido Aaron Mendes, directed the Red Cross Hospital in Rome during the 1930s. As Italian Fascist law instituted a regime of prejudice against Jews in Italy, he moved his family to Switzerland to await British permission to enter the territory of Palestine, later to become the state of Israel. These certificates were obtained with the direct intervention of Pope Pius 12th, a classmate and close friend to Guido. The family moved to Gedera in Israel where David’s father, Maor Mendes and his grandfather pioneered the treatment and obliteration of Tuberculosis in Israel. During the 1947–1949 Palestine war the family moved to Ramat Gan, where he graduated from Ohel Shem high school. During his time in Ramat Gan, he practiced fencing and went on to become captain of the Israeli team. He won all national foil competitions in Israel between the years 1955 and 1963. He then joined the army and married his childhood friend, Nili Shmueli. In 1965 David relocated with his family to the United States to continue his training. He remained in New York City until 1975 when he returned to Israel with his wife and two children, Ido and Sharone. His third child, Yonni, was born in Haifa a few years later.
Sources: en.wikipedia.org
=== Animals === Animals have senses, are able to move, and have physical appetites. Apex predators like the lion could move vigorously, and has powerful senses like keen eyesight and the ability to smell their prey from a distance, while a lower order of animals might wiggle or crawl, or like oysters were sessile, attached to the sea-bed. All, however, share the senses of touch and taste.
He signed the Epstein Files Transparency Act on November 19, and made a lengthy post on Truth Social which included the claim, "Do not forget — The Biden Administration did not turn over a SINGLE file or page related to Democrat Epstein, nor did they ever even speak about him.
Positive bottles with negative Gram stains are subcultured before being returned to the incubator, often using special culture media that promotes the growth of slow-growing organisms. It typically takes 24 to 48 hours for sufficient growth to occur on the subculture plates for definitive identification to be possible. At this point, the microbiologist will assess the appearance of the bacterial or fungal colonies and carry out tests that provide information about the metabolic and biochemical features of the organism, which permit identification to the genus or species level. For example, the catalase test can distinguish streptococci and staphylococci (two genera of Gram-positive cocci) from each other, and the coagulase test can differentiate Staphylococcus aureus, a common culprit of bloodstream infections, from the less pathogenic coagulase-negative staphylococci.
== Education and career == Pentelute grew up in San Diego, California, and earned both his B.A. in Psychology and B.S. in Chemistry from the University of Southern California in 2003. He continued his studies at the University of Chicago, where he earned his M.S. and Ph.D. in chemistry in the laboratory of Stephen Kent. After receiving his Ph.D., Pentelute served as a senior scientist at Ethos Pharmaceuticals in 2008. He completed a postdoctoral fellowship at Harvard Medical School from 2008 to 2011 with R. John Collier in Microbiology. In 2011, Pentelute began his assistant professorship at the Massachusetts Institute of Technology (MIT), was awarded tenure in 2017 and promoted to Professor of Chemistry in 2021.
=== Vascular and metabolic disease expression === ITGA1 expression is also altered in non-cancer disease states. In diabetic foot ulcers (DFU), ITGA1 is upregulated in wound tissues from diabetic patients and in advanced glycation and end product (AGE)-treated human endothelial cells. Increased ITGA1 expression is associated with endothelial dysfunction, impaired proliferation and migration, reduced tube formation, and increased cellular senescence. Reduction of ITGA1 expression improves endothelial functional responses, suggesting that disease-associated ITGA1 activation contributes to impaired wound healing.
Sources: en.wikipedia.org
===== Type 2N (Normandy) ===== Type 2N VWD results from a loss-of-function mutation that reduces the binding of von Willebrand factor (VWF) to factor VIII. Although VWF antigen (quantity) and activity levels (Ristocetin cofactor assay) remain normal, factor VIII levels are typically low (usually 5-15%) due to impaired VWF binding. This vulnerability to proteolysis in the circulation leads to clinical manifestations resembling those of Hemophilia A. The significantly reduced factor VIII levels in VWD Type 2N can sometimes lead to misdiagnosis as mild Hemophilia A. Like Hemophilia A, VWD Type 2N presents with joint and soft tissue bleeds. It is an autosomal recessive disorder, requiring either homozygosity or double heterozygosity for disease manifestation. Diagnostic tools include assessing the ratio of VWF binding to VWF antigen levels. A ratio <0.3 indicates homozygous or double heterozygous VWD Type 2N, while a ratio <0.5 suggests heterozygous VWD Type 2N. Conversely, a VWF antigen-to-binding ratio >3 confirms the diagnosis of VWD Type 2N. Ristocetin-Induced Platelet Agglutination (RIPA) and VWF multimer analysis are typically normal.
== Limitations == Like other staining methods, Van Gieson’s stain has limitations. It may miss very thin collagen fibrils, immature collagen can be faint or invisible with this stain. This can lead to an underestimation of collagen content. The red coloration can also fade if slides are not properly fixed or stored. The usage of the picric acid–acid fuchsin mixture tends to remove or significantly weaken majority of hematoxylin, resulting in nuclei that are faint or nearly invisible under the microscope.To overcome this, an iron-mordanted hematoxylin, such as Weigert’s hematoxylin, is typically used. Iron hematoxylins are more resistant to acid decolorization and preserve nuclear detail even after exposure to Van Gieson's solution.
== Structure == Type III collagen is synthesized by cells as a pre-procollagen; the human preproα1(III) chain is 1466 amino acids long, comprising an N-terminal signal peptide (residues 1–23), an N-terminal propeptide, the roughly 1000-residue triple-helical domain, and a C-terminal propeptide. The signal peptide is cleaved off producing a procollagen molecule. Three identical type III procollagen chains come together at the carboxy-terminal ends, and the structure is stabilized by the formation of disulphide bonds. Each individual chain folds into a left-handed helix and the three chains are then wrapped together into a right-handed superhelix, the triple helix. Prior to assembling the super-helix, each monomer is subjected to a number of post-translational modifications that occur while the monomer is being translated. First, on the order of 145 prolyl residues of the 239 in the triple-helical domain are hydroxylated to 4-hydroxyproline by prolyl-4-hydroxylase. Second, some of the lysine residues are hydroxylated or glycosylated, and some lysine as well as hydroxylysine residues undergo oxidative deamination catalysed by lysyl oxidase. Other post-translational modifications occur after the triple helix is formed. The large globular domains from both ends of the molecule are removed by C- and amino(N)-terminal-proteinases to generate triple-helical type III collagen monomers called tropocollagen. In addition, crosslinks form between certain lysine and hydroxylysine residues.
=== Abuse === Unlike other carbamates such as meprobamate and its prodrug carisoprodol, methocarbamol has greatly reduced abuse potential. Studies comparing it to the benzodiazepine lorazepam and the antihistamine diphenhydramine, along with placebo, find that methocarbamol produces increased "liking" responses and some sedative-like effects; however, at higher doses dysphoria is reported. It is considered to have an abuse profile similar to, but weaker than, lorazepam.
Sources: en.wikipedia.org
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.
The peptide enters plasma rapidly and is broken down by ordinary proteases into amino acids and shorter fragments. Reported half-lives are short. Whether meaningful amounts of the intact molecule reach the brain is an open question.
Most clinical reports are small, published in Russian and not independently replicated. English-language reviews highlight the absence of large randomised trials. Conclusions about efficacy should be treated as provisional.
Selank is a synthetic heptapeptide designed as a stabilized analog of the natural tetrapeptide tuftsin. It has been investigated mainly for anxiolytic and cognitive effects. It is not an approved pharmaceutical in most countries.